Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action

European Respiratory Journal

Volumn 9, Issue 8, 1996, Pages 1684-1688

  Van Noord, J A ^a   Smeets, J J ^a   Raaijmakers, J A M ^b   Bommer, A M ^b   Maesen, F P V ^a  

^a De Wever Hospital ^*  (Netherlands)

^b GLAXOSMITHKLINE   (Netherlands)

Author keywords

Asthma; Formoterol; Salmeterol

Indexed keywords

FORMOTEROL; SALMETEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029758728     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09081684     Document Type: Article

References (26)

1. Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PGMA. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest 1990; 97: 590-594.
2. 2-agonists by comparison of inhaled formoterol vs inhaled salbutamol. Eur Respir J 1989; 2: 652S.
3. Maesen FPV, Costongs R, Smeets S, Zweers PGMA, Goedhart DM. Formoterol as dry powder inhalation, a dose-finding study in comparison with formoterol metered-dose inhaler and placebo. Chest 1992; 101: 1376-1381.
4. Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611-614.
5. Boyd G, Andersen K, Carter R. Placebo-controlled comparison of the bronchodilator performance of salmeterol and salbutamol over 12 hours. Thorax 1990; 45: A340.
6. Arvidsson P, Larsson D, Lofdahl CG. Objective and subjective bronchodilation over 12 hours after inhaled formoterol: individual responses. J Asthma 1993; 30: 459-465.
7. Linsen VMJ, Bindels HJC, Van Noord JA. A direct comparison of the time of onset of action between inhaled formoterol and salmeterol. Eur Respir J 1993; 6: S591.
8. Naline E, Zhang Y, Qian Y, et al. Relaxant effects and durations of action of formoterol and salmeterol in the isolated human bronchus. Eur Respir J 1994; 7: 914-920.
9. Nials AT, Coleman RA, Johnson M, Magnussen H, Rabe KF, Vardey CJ. Effects of β-adrenoceptor agonists in human bronchial smooth muscle. Br J Pharmacol 1993; 110: 1112-1116.
10. Sykes AP, Ayres JG. A study of the duration of the bronchodilator effect of 12 μg and 24 μg of inhaled formoterol and 200 μg inhaled salbutamol in asthma. Respir Med 1990; 84: 135-138.
11. Kemp JP, Bierman CW, Cocchetto DM. Dose response study of inhaled salmeterol in asthmatic patients with 24 hour spirometry and Holter monitoring. Ann of Allergy 1993; 70: 316-322.
12. 2-adrenoceptor agonist: a comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
13. 2-agonist with prolonged duration of action. Lung 1993; 171: 249-264.
14. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103-107.
15. Cazzola M, Matera MG, Santangelo A, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362.
16. American Thoracic Society. Standards for the diagnosis and care of patients with COPD and asthma. Am Rev Respir Dis 1987; 136: 225-244.
17. Maesen FPV, Costongs RJMG, Smeets JJ, Brombacher PJ, Zweers PGMA. The effect of maximal doses of formoterol and salbutamol from a metered-dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991; 99: 1367-1373.
18. Wegener Th, Hedenström H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992; 102: 535-538.
19. Viljanen A. Reference values for spirometric, pulmonary diffusing capacity and body plethysmographic studies. Scand J Clin Lab Invest 1982; 42 (Suppl. 159): 1-50.
20. Anderson GP, Linden A, Rabe KF. Why are long-acting β-adrenoceptor agonists long-acting? Eur Respir J 1994; 7: 569-578.
21. 2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145-2160.
22. Johnson M. Salmeterol. Med Res Rev 1995; 15: 225-257.
23. Maesen FPV, Smeets SJ, Costongs MAL, Zweers PGMA, Pfeil JPJ. Onset of action of formoterol by dry powder inhaler: objective and subjective measures. Br J Clin Pharmacol 1995; 49: 294-296.
24. Rabe KF, Jörres R, Nowak D, Behr N, Magnussen H. Comparison of the effect of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436-1441.
25. Zellweger JP, Pfenninger M, Ruff P, et al. Twenty four hour protective effect of salmeterol xinafoate (50 μg) against methacholine-induced bronchoconstriction in mild-to-moderate asthmatic patients; a randomized, double-blind, cross-over, single-dose trial. Eur Respir J 1994; 7 (Suppl. 18): 422s.
26. NHLBI/WHO Workshop report. Global initiative for asthma. Bethesda, NIH, 1995.